Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice
Jayashri Kulkarni, Sacha Filia, Lesley Berk, Kate Filia, Seetal Dodd, Anthony de Castella, Alan JM Brnabic, Amanda J Lowry, Katarina Kelin, William Montgomery, Paul B Fitzgerald, Michael Berk
BMC PSYCHIATRY | BMC | Published : 2012
Funding for this study was provided by Eli Lilly Australia. The chief study investigators (J. Kulkarni and M. Berk) are independent academic clinicians and directed the study design and conduct. Lilly Medical employees were involved in study design, analysis and interpretation of data, and in the writing of the report. The Lilly authors listed (A. Brnabic, W. Montgomery, K. Kelin and A. J. Lowry) participated in the decision to submit the paper for publication. Lilly had no role in data collection.J. Kulkarni, P. B. Fitzgerald, A. de Castella, and S. Dodd have received research funding and/or speaker's fees and/or funding to attend conferences from Eli Lilly. M. Berk has received grant/research support from the Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier; has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Pfizer, Sanofi Synthelabo, Servier, Solvay, Wyeth and acted as a consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, and Servier. L. Berk is supported by an NHMRC scholarship. W. Montgomery, K. Kelin, and A. J. Lowry are employees of Eli Lilly Australia. A. Brnabic was employed by Eli Lilly Australia at the time of manuscript development.Research was supported by Eli Lilly and Company.